Heather Jacene, MD, has assumed the prestigious role of president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), marking a significant milestone in the advancement of nuclear medicine and molecular imaging disciplines. Dr. Jacene’s appointment was announced during the SNMMI 2026 Annual Meeting held from May 30 to June 2 in Los Angeles, an event that gathers experts and pioneers driving innovation in precision medicine and molecular diagnostics. Her leadership is poised to catalyze new developments that integrate cutting-edge research with clinical practice, deepening the impact of molecular imaging technologies on patient outcomes.
In her multifaceted career, Dr. Jacene holds several prominent positions, including Chief of Molecular Imaging and Theranostics at Beth Israel Deaconess Medical Center, Clinical Director of Nuclear Medicine/PET-CT, and Senior Physician at Dana-Farber Cancer Institute. She also serves as Associate Professor of Radiology at Harvard Medical School. Her diverse roles underscore a strong commitment to pushing the boundaries of nuclear medicine through both clinical excellence and academic rigor, highlighting her capacity to bridge the gap between innovative research and patient-centered care.
One of Dr. Jacene’s primary objectives as president is to reinforce SNMMI as an indispensable resource for its members, spanning the spectrum from foundational basic science research to the highest standards of evidence-based clinical application. She emphasizes the critical importance of fostering an environment where nuclear medicine evolves through interdisciplinary collaboration and robust scientific inquiry, ensuring that the field remains at the forefront of diagnostic and therapeutic modalities.
Dr. Jacene is focused on creating dynamic platforms within SNMMI that encourage active participation and collaboration among members, transcending traditional disciplinary boundaries. By promoting multidisciplinary partnerships, she envisions expanding the reach and influence of nuclear medicine, driving innovations that enhance molecular imaging technologies such as PET-CT and radiopharmaceutical therapies. Her approach involves breaking down silos to facilitate knowledge exchange and accelerate technological advancements.
A major part of her agenda involves advocating for increased awareness and acceptance of nuclear medicine among clinical colleagues and patients alike. She aims to communicate the tangible benefits of these advanced imaging techniques in personalized medicine, emphasizing how molecular imaging enables precise characterization of disease states and therapeutic responses. This strategic communication will help solidify nuclear medicine’s role as a cornerstone of modern clinical practice.
Another critical challenge Dr. Jacene intends to address involves the barriers related to the availability, reimbursement, affordability, and funding of radiopharmaceuticals. These radiotracers are indispensable tools in targeted diagnostic and therapeutic procedures, yet their accessibility remains uneven. Her leadership will concentrate on policy advocacy and operational innovations to ensure broader and timely access to these vital agents, thus enhancing the clinical utility and patient reach of nuclear medicine.
Dr. Jacene’s extensive training and expertise reflect a career dedicated to nuclear medicine and molecular imaging. She earned her medical degree from the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School in New Brunswick, New Jersey. She subsequently completed both her residency and fellowship in nuclear medicine and PET-CT at Johns Hopkins University, Baltimore, where she honed her skills in cutting-edge diagnostic imaging techniques and the evolving applications of radiopharmaceuticals in oncology and beyond.
Her longstanding involvement with SNMMI is marked by significant leadership roles, including chairing the Scientific Program Committee, where she orchestrated innovative transformations to the Annual Meeting format. These changes have led to enhanced member engagement, increased networking opportunities, and a fertile ground for presenting novel research. She has also played a pivotal role in quality assurance, serving as Chair for the Quality of Practice Domain within the SNMMI Value Initiative, and helped establish the Radiopharmaceutical Centers of Excellence Program to standardize and elevate the delivery of radiopharmaceutical therapies.
Dr. Jacene’s research portfolio is both extensive and impactful, focusing predominantly on the application of FDG-PET/CT and other emerging PET tracers for the assessment of cancer biology and therapeutic efficacy. Her investigations delve into functional imaging biomarkers that reveal tumor metabolism, receptor expression, and microenvironmental changes, thereby informing more personalized and adaptive treatment strategies. Furthermore, she explores novel radiopharmaceutical therapies that promise to revolutionize the management of malignancies through targeted molecular interventions.
In addition to more than 100 peer-reviewed scientific publications, Dr. Jacene has authored numerous review articles and book chapters, contributing authoritative perspectives on the evolving landscape of molecular imaging and theranostics. Her scholarship not only advances academic discourse but also aids in translating complex imaging science into practical clinical guidelines and protocols that optimize patient care.
The new SNMMI leadership team for 2026-27 includes other distinguished figures such as Gary Ulaner, MD, PhD, FSNMMI, chosen as president-elect, and Jason S. Lewis, PhD, FSNMMI, as vice president-elect. The SNMMI Technologist Section has also elected Shannon Youngblood, EdD, MSRS, CNMT, RT(CT), as president, with Sara L. Johnson, CNMT, RT(N)(CT), serving as president-elect. Together, this leadership cadre represents a diverse spectrum of expertise poised to drive the society’s mission forward.
SNMMI remains a global scientific and medical organization dedicated to propelling nuclear medicine, molecular imaging, and theranostic precision medicine. Through its efforts, SNMMI facilitates innovations that allow clinicians to tailor diagnostic and therapeutic approaches to individual patients with unprecedented specificity, aiming for optimal outcomes. Dr. Jacene’s presidency symbolizes a sustained commitment to integrating high-caliber research, education, and clinical practice at the forefront of this transformative field.
Subject of Research:
Heather Jacene’s presidency at SNMMI and advancements in nuclear medicine and molecular imaging, including PET-CT innovations and radiopharmaceutical therapy.
Article Title:
Heather Jacene, MD, Named President of the Society of Nuclear Medicine and Molecular Imaging: Advancing the Future of Molecular Imaging and Theranostics
News Publication Date:
June 2026
Web References:
http://www.snmmi.org/
Image Credits:
Courtesy of SNMMI
Keywords:
Molecular imaging, Nuclear medicine, Positron emission tomography, Personalized medicine, Radiopharmaceutical therapy, Theranostics, FDG-PET/CT, Radiopharmaceutical Centers of Excellence, Precision medicine, SNMMI, Cancer imaging, Clinical molecular imaging
